Bio-Rad Lab's Q1 2024 earnings reported mixed results, with a 9.8% net sales decrease to $610.8m, but net income increased to $383.9m.
Bio-Rad Laboratories reported Q1 2024 earnings with mixed results. Total net sales decreased 9.8% to $610.8m but net income increased to $383.9m. Life Sciences segment sales dropped 25.3%, while Clinical Diagnostics sales rose 4.7%. Despite a weak biotech spending environment and slow demand in China, Bio-Rad reaffirmed a 1-2.5% sales growth forecast for 2024, expecting a gradual recovery in the biopharma market in the second half.
May 07, 2024
4 Articles